Altamira Therapeutics .(CYTO) - 2025 H1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total operating expenses decreased from $3.9 million in 2024 to $2.6 million in 2025, a decline of 32.9% driven by lower general and administrative expenses and reduced R&D expenditure [16] - Net loss decreased by 64.6% to $1.5 million in 2025 compared to $4.3 million in 2024, primarily due to finance income of $1.7 million from the appreciation of intercompany loans [16] - Cash used in operations decreased by 56.8% from $3.2 million in the first half of 2024 to $1.4 million in 2025 [16] - Shareholders' equity amounted to $4.1 million as of June 30, 2025, compared to $6.6 million at year-end 2024 [16] Business Line Data and Key Metrics Changes - The company is transitioning to a platform model focusing on RNA delivery, which has led to a decrease in spending levels [15] - Significant progress in the RNA delivery business, with a focus on particle formulation and process development [8][9] - The company has established collaborations with multiple partners in the biotech and pharma industry, expanding its licensing strategy [11] Market Data and Key Metrics Changes - The circular RNA market is projected to grow at a rate of 15.2% from 2026 to 2033, potentially reaching $5.2 billion by 2033 [12] Company Strategy and Development Direction - The company plans to spin off a majority of its Swiss subsidiary, Altamira Therapeutics AG, to attract private equity investment [5][6] - The focus will shift to managing and monetizing legacy assets while enhancing the RNA delivery business [17][19] - The company aims to position itself as a classic holding company post-spin-off, with a focus on funding operations through various means [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in the RNA delivery business and the potential for growth in RNA therapeutics [18][19] - The company acknowledges challenges in raising public market funding and is pursuing a different route with private equity involvement [18] Other Important Information - The company has made progress in transitioning its legacy products, including the BENCHEO nasal spray and AM-125 nasal spray, to new production sites and regulatory classifications [13][14] - A patent for AM-125 was obtained in Japan, expanding its intellectual property protection [14] Q&A Session Summary - No specific questions or answers were documented in the provided content.